About Aptevo Therapeutics Inc. - Common Stock (APVO)
Aptevo Therapeutics is a biotechnology company focused on developing innovative therapies for serious diseases, with a particular emphasis on oncology and hematology. The company specializes in the creation and commercialization of various therapeutic protein products, including antibodies and other biologics, aimed at harnessing the immune system to target and treat cancers and other critical health conditions. Aptevo's research and development efforts are driven by a commitment to improving patient outcomes through advanced scientific approaches and cutting-edge technology, positioning the company at the forefront of medical innovation. Read More
The company stated that the 100% remission rate achieved at the highest dose level of the trial demonstrated the drug’s potential to redefine the frontline treatment landscape for newly diagnosed AML patients who are unfit for intensive chemotherapy.
TOMI Environmental Solutions (NASDAQ: TOMZ) is quietly redefining global health and safety standards with its patented SteraMist® platform, a breakthrough disinfection technology that is faster, safer, and more effective than traditional methods. Powered by Binary Ionization Technology (BIT), originally developed under a DARPA grant, SteraMist® achieves a six-log kill rate within seconds while leaving behind only oxygen and water vapor. Its proven attributes make it especially valuable for hospitals, pharmaceutical cleanrooms, and food production facilities.
ORLANDO, FL / ACCESS Newswire / September 5, 2025 / RedChip Companies will air interviews with Foremost Clean Energy Ltd. (NASDAQ:FMST) and Aptevo Therapeutics, Inc. (NASDAQ:APVO) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, September 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
New candidates, APVO452 and APVO451, harness proprietary ADAPTIR-FLEXTM design to target prostate and multiple solid tumor cancers by simultaneously engaging tumor antigens, T cells, and immunosuppressive cells
Mipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types
ORLANDO, FLORIDA / ACCESS Newswire / August 8, 2025 / RedChip Companies will air interviews with Aptevo Therapeutics, Inc. (NASDAQ:APVO) and 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, August 9, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top gainers and losers in today's session.
SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of its previously announced offering of (i) 2,465,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 12,325,000 shares of its common stock (the "Common Warrants") at a purchase price of $3.25 per share and associated Common Warrants in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with five Common Warrants, each to purchase one share of common stock. The Common Warrants have an exercise price of $3.25 per share, are exercisable upon stockholder approval, and will expire five years following the date stockholder approval.
